CONTENTS

General InformationGeneral Information Operational DataOperational Data

Consolidated Consolidated HealthcareHealthcare Personal Care Personal Care Property DevelopmentProperty Development

Future Strategies

General Information General Information ShareholdersShareholders Affiliates and SubsidiariesAffiliates and Subsidiaries Current Consolidated Current Consolidated StructureStructure

ECZACIBAŞI İLAÇ, SINAİ VE FİNANSAL YATIRIMLAR

SHAREHOLDERS

TRADE NAME SHARE (TRY)CAPITAL SHARE

(%)

ECZACIBAŞI HOLDİNG CO. 277.476.368 50,62

ECZACIBAŞI INVESTMENT HOLDİNG CO. 109.904.847 20,05

PUBLICLY HELD PART 160.826.785 29,33

TOTAL 548.208.000 100,00

AFFILIATES AND SUBSIDIARIES

AFFILIATES SHARE

PER CENT (%)

NOMINAL PARTICIPATION

(TRY) CAPITAL

(TRY)

Eczacıbaşı-Baxter Hospital Supply Co. 50,0 35.319.209 70.643.969Eczacıbaşı-Monrol Nuclear Products Co. 50,0 12.499.900 25.000.000Eczacıbaşı-Beiersdorf Cosmetic Products Co. 50,0 399.923 800.000Eczacıbaşı-Pharmaceuticals (Cyprus) Ltd. 50,0 31.350 62.700Eczacıbaşı-Girişim Co. 48,1 3.922.595 8.150.000Eczacıbaşı-Schwarzkopf Professional Hairdressers’ Products Co. 47,0 1.175.000 2.500.000

Eczacıbaşı Holding Co. 37,3 79.408.613 213.000.000Ekom Eczacıbaşı› Foreign Trade Co. 26,4 917.666 3.481.000VitrA Tiles Co. 25,0 28.250.000 113.000.000Eczacıbaşı Information and Communication Technologies Co. 11,2 484.626 4.323.000

SUBSIDIARIES SHARE

PER CENT (%)

NOMINAL PARTICIPATION

(TRY) CAPITAL

(TRY)

EHP Eczacıbaşı Health Care Products Joint Stock Co. 100,0 1.894.830 1.894.830EIP Eczacıbaşı Pharmaceuticals Marketing Co. 99,9 41.966.400 42.000.000Eczacıbaşı Property Development and Investment Co. 99,5 84.570 85.000EIP Eczacıbaşı Pharmaceuticals Trading Co. 94,7 47.350 50.000

CURRENT CONSOLIDATED STRUCTURE

Property Property DevelopmentDevelopment

• Ecz. Property Dv. %99,5

• Kanyon AVM %50,0

• Kanyon Office %100,0

• Ormanada Project %50,0

Personal Care Personal Care

• Ecz.-Beiersdorf %50,0

• Ecz.-Girişim Co. %48,1

• Ecz.-Schwarzkopf %47,0

EİS

HealthcareHealthcare

• Ecz. Pharma. Marketing %99,9

• Ecz. Pharma. Trading %94,7

• Ecz.-Baxter Hospital S. %50,0

• Ecz. Pharma(Cyprus)

%50,0

• Ecz.-Monrol

%50,0

• Ecz. Health Services

%46,5

OtherOther

• Ecz. Holding %37,3

• Ecz.Frgn Trd.%26,4

• Vitra Karo %25,0

• Ecz. Inf. Com.%14,0

ECZACIBAŞI İLAÇ, SINAİ VE FİNANSAL YATIRIMLAR

Operational DataOperational Data ConsolidatedConsolidated HealthcareHealthcare Personal CarePersonal Care Property DevelopmentProperty Development

0100200300400500600700800900

1.000 874,7 913,2

15,450,7

14,5

60,4275,7

CONSOLIDATED NET SALES

CONSOLIDATED NET PROFIT

2009

2010

2009 - 2010 CONSOLIDATED INDICATORS

(MIO TRY)

CONSOLIDATED OPERATING PROFIT

290,2

2009 - 2010 CONSOLIDATED INDICATORS

(MIO TRY) 2009 2010 ∆ (%)

Consolidated Total Assets: 2.489 2.662 7

Consolidated Total Equities: 2.190 2.387 9

Equities / Assets: 88 90 2

2010 CONSOLIDATED SEGMENT DEVELOPMENTS– HEALTHCARE–

INDUSTRIAL DEVELOPMENTSINDUSTRIAL DEVELOPMENTS Turkish Republic Social Security Corporation, claiming that with regard to the 2010 medical expenses, the figures agreed with the industry were exceeded, increased public discount by 9.5% in all medicines with a sales price over TRY 10.Thereby, the public discount ratio of the original medicines without an equivalent was raised to 32.5%, while that of the original medicines with equivalent and the equivalent medicines themselves was raised to 20.5%. We are taking measures as necessary in an effort to reduce impacts of those resolutions on the operating profitability.

2010 CONSOLIDATED SEGMENT DEVELOPMENTS– HEALTHCARE–

DEVELOPMENTS IN OPERATIONS

The new products lauched by Eczacibasi Ilac Pazarlama in 2010

The new product portfolios of 2010 and 2011 are expected to have a contribution equal to appr. 25.5 mio TRY on the 2011 net sales

The new products we plan to launch in 2011:

2010 CONSOLIDATED SEGMENT DEVELOPMENTS– HEALTHCARE –

OPERATIONAL DEVELOPMENTS Eczacıbaşı-Monrol;

The radiopharmaceutical (FDG) production plant in Istanbul Technopark was completed in 2010.

The FDG production plant investments, continuing in Antalya

and Malatya in Turkey and, in Romania in abroad, will

be completed in 2011.

The endeavors related to acquisition of 99.996% share of Molekuler Goruntuleme Tic. Ve San. A.S. are continuing and is expected to be completed in June 2011.

In 2011, we are planning to establish FDG production plants in Poland and Egypt.

(MIO TRY)

0

100

200

300

400

500

NET SALES OPERATING PROFIT

369,1

3,3

355,7

23,3

2009

2010

2009 - 2010 CONSOLIDATED SEGMENT INDICATORS– MEDICAL–

MENICON PARTNERSHIP

Eczacıbaşı İlaç Pazarlama,

Executed a contract on 01 November 2010 with Menicon, Japan’s

first and largest contact lens and lens care products manufacturer,

operating in more than 30 countries including Europe, USA and

Japan with over 1.000 employees, for marketing and sales rights in

Turkey Supported by a strong licensor, we are now in the

ophthalmology business. (Keratokonus) Menicon lenses are the best lenses in the world with

regard to the hard lenses and those manufuctured for personal treatment.

We are targeting a 20% market share in the contact lens and lens care

products market, which has an approximate size of 50 mio TRY

2010 CONSOLIDATED SEGMENT DEVELOPMENTS– PERSONAL CARE–

On the basis of TRY in 2010; Fast Consumption Products Market 9%*, Personal Care Market 6,5%, Cosmetics sub-market grew by 8.6%. The competition increased in all fields where we operate.

(*) AC Nielsen, 2010 Q4 FMCG Track, Total Trade Volume excluding cigarattes, TRY

(MIO TRY)

0

100

200

300

400

500

600

NET SALES OPERATING PROFIT

472,3

12,0

514,7

19,7

2009

2010

2009 - 2010 CONSOLIDATED SEGMENT INDICATORS –PERSONAL CARE-

2010 CONSOLIDATED SEGMENT DEVELOPMENTS– PROPERTY DEVELOPMENT–

KANYON:KANYON:

EIS owns 100% of the office block and 50% of the Shopping Center. The Kanyon Shopping Center took its place as a life center in the middle of

the city, in addition to being a shopping center, it preserved its quality as the

shopping center which offers many renovations thanks to the attempts

took place in 2010. Given the increasing competition in the industry through the new shopping

center openings, Kanyon focused on activities which could impose

differences (marketing activities, placement of brands with a high customer

attraction and traffic potential, reinforcing the brand spectrum) The number of visitors to Kanyon increased by 9% in 2010.

ORMANADA PROJECT:ORMANADA PROJECT:

50% of the 22 lots covering 196.410 m2 in total is owned by EIS.

The properties are plots with a development license, they are licensed for housing, and partially for commercial purposes.

Total construction area is expected to be about 90 thousand m2. The construction works were commenced in the last quarter of 2010.

The application and internal design project works carried out by different architectural groups have been completed, and the total number of housing units in the project is assumed to be 270.

2010 CONSOLIDATED SEGMENT DEVELOPMENTS– PROPERTY DEVELOPMENT–

(M IO TL)

% 22

% 49

0

20

40

60

NET SALES OPERATING PROFIT

33,3

15,7

42,9

18,1

2009

2010

2009 - 2010 CONSOLIDATED SEGMENT INDICATORS

– PROPERTY DEVELOPMENT–

Future StrategiesFuture Strategies

EIS ECZACIBASI PHARMACEUTICAL AND INDUSTRIAL INVESTMENT CO.

MEDICAL INDUSTRYMEDICAL INDUSTRY Procuring strong licensors, brands and strategical partnerships, Acquiring licenses and offering new products to the market in a short tim Focusing particularly on biotechnology products in order to expand our biotech product range,Establishing new nuclear medicine production plants in or outside Turkey and realize new investments in R&D, Increasing the number of Evital Units which provide services to patients who need care,Penetrating new fields in medical industry.

PERSONAL CAREPERSONAL CAREContinuing our current leadership in the fast consumed products industryPenetrating to other categories in the “fast consumed products” market, with a focus on “personal care products” which provide synergy.

FUTURE STRATEGIES

PROPERTY DEVELOPMENT

Completing the ongoing projects Developing new commercial properties in the areas with high

development potential

BANKING

On 31 December 2009, we applied to Turkish Banking Supervision and Organization Board for the purpose of establishing an Investment Bank. In the event necessary permissions are received after having completed the legal processes, we decided to participate in the bank’s capital by 40%.

FUTURE STRATEGIES